|
|
![]() |
|
|||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
First published online June 18, 2008
doi: 10.1242/10.1242/jcs.017897
Commentary |
1 FIRC Institute of Molecular Oncology, Via Adamello 16, 20139, Italy
2 School of Sciences, University of Milan, Milan, Italy
3 Mario Negri Institute for Pharmacological Research, Via La Masa 19, 20156 Milan, Italy
* Author for correspondence (e-mail: elisabetta.dejana{at}ifom-ieo-campus.it)
Accepted 9 May 2008
Endothelial cells control the passage of plasma constituents and circulating cells from blood to the underlying tissues. This specialized function is lost or impaired in several pathological conditions – including inflammation, sepsis, ischemia and diabetes – which leads to severe, and sometimes fatal, organ dysfunction. Endothelial permeability is regulated in part by the dynamic opening and closure of cell-cell adherens junctions (AJs). In endothelial cells, AJs are largely composed of vascular endothelial cadherin (VE-cadherin), an endothelium-specific member of the cadherin family of adhesion proteins that binds, via its cytoplasmic domain, to several protein partners, including p120, β-catenin and plakoglobin. Endogenous pathways that increase vascular permeability affect the function and organization of VE-cadherin and other proteins at AJs in diverse ways. For instance, several factors, including vascular endothelial growth factor (VEGF), induce the tyrosine phosphorylation of VE-cadherin, which accompanies an increase in vascular permeability and leukocyte diapedesis; in addition, the internalization and cleavage of VE-cadherin can cause AJs to be dismantled. From the knowledge of how AJ organization can be modulated, it is possible to formulate several pharmacological strategies to control the barrier function of the endothelium. We discuss the possible use of inhibitors of SRC and other kinases, of agents that increase cAMP levels, and of inhibitors of lytic enzymes as pharmacological tools for decreasing endothelial permeability.
Key words: Permeability, VE-cadherin, Adherens junctions, Endothelial cells
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati
Twitter What's this?
This article has been cited by other articles:
![]() |
W.-M. Heupel, A. Efthymiadis, N. Schlegel, T. Muller, Y. Baumer, W. Baumgartner, D. Drenckhahn, and J. Waschke Endothelial barrier stabilization by a cyclic tandem peptide targeting VE-cadherin transinteraction in vitro and in vivo J. Cell Sci., May 15, 2009; 122(10): 1616 - 1625. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Atar, P. Petzelbauer, J. Schwitter, K. Huber, B. Rensing, J. D. Kasprzak, C. Butter, L. Grip, P. R. Hansen, T. Suselbeck, et al. Effect of Intravenous FX06 as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction: Results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) Trial J. Am. Coll. Cardiol., February 24, 2009; 53(8): 720 - 729. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Martinelli, M. Gegg, R. Longbottom, P. Adamson, P. Turowski, and J. Greenwood ICAM-1-mediated Endothelial Nitric Oxide Synthase Activation via Calcium and AMP-activated Protein Kinase Is Required for Transendothelial Lymphocyte Migration Mol. Biol. Cell, February 1, 2009; 20(3): 995 - 1005. [Abstract] [Full Text] [PDF] |
||||